O'Malley Brendan, Lazinski David W
Department of Molecular Biology and Microbiology, Tufts University School of Medicine, 150 Harrison Ave., Boston, MA 02111, USA.
J Virol. 2005 Jan;79(2):1142-53. doi: 10.1128/JVI.79.2.1142-1153.2005.
The large hepatitis delta antigen (HDAg-L) mediates hepatitis delta virus (HDV) assembly and inhibits HDV RNA replication. Farnesylation of the cysteine residue within the HDAg-L carboxyl terminus is required for both functions. Here, HDAg-L proteins from different HDV genotypes and genotype chimeric proteins were analyzed for their ability to incorporate into virus-like particles (VLPs). Observed differences in efficiency of VLP incorporation could be attributed to genotype-specific differences within the HDAg-L carboxyl terminus. Using a novel assay to quantify the extent of HDAg-L farnesylation, we found that genotype 3 HDAg-L was inefficiently farnesylated when expressed in the absence of the small hepatitis delta antigen (HDAg-S). However, as the intracellular ratio of HDAg-S to HDAg-L was increased, so too was the extent of HDAg-L farnesylation for all three genotypes. Single point mutations within the carboxyl terminus of HDAg-L were screened, and three mutants that severely inhibited assembly without affecting farnesylation were identified. The observed assembly defects persisted under conditions where the mutants were known to have access to the site of VLP assembly. Therefore, the corresponding residues within the wild-type protein are likely required for direct interaction with viral envelope proteins. Finally, it was observed that when HDAg-S was artificially myristoylated, it could efficiently inhibit HDV RNA replication. Hence, a general association with membranes enables HDAg to inhibit replication. In contrast, although myristoylated HDAg-S was incorporated into VLPs far more efficiently than HDAg-S or nonfarnesylated HDAg-L, it was incorporated far less efficiently than wild-type HDAg-L; thus, farnesylation was required for efficient assembly.
大丁型肝炎抗原(HDAg-L)介导丁型肝炎病毒(HDV)组装并抑制HDV RNA复制。这两种功能都需要HDAg-L羧基末端的半胱氨酸残基进行法尼基化修饰。在这里,我们分析了来自不同HDV基因型的HDAg-L蛋白和基因型嵌合蛋白掺入病毒样颗粒(VLP)的能力。观察到的VLP掺入效率差异可归因于HDAg-L羧基末端的基因型特异性差异。使用一种新的检测方法来量化HDAg-L法尼基化修饰的程度,我们发现当在没有小丁型肝炎抗原(HDAg-S)的情况下表达时,3型HDAg-L的法尼基化修饰效率低下。然而,随着细胞内HDAg-S与HDAg-L的比例增加,所有三种基因型的HDAg-L法尼基化修饰程度也随之增加。我们筛选了HDAg-L羧基末端的单点突变,鉴定出三个严重抑制组装但不影响法尼基化修饰的突变体。在已知突变体能够进入VLP组装位点的条件下,观察到的组装缺陷仍然存在。因此,野生型蛋白中的相应残基可能是与病毒包膜蛋白直接相互作用所必需的。最后,观察到当HDAg-S被人工豆蔻酰化时,它可以有效地抑制HDV RNA复制。因此,与膜的普遍结合使HDAg能够抑制复制。相比之下,虽然豆蔻酰化的HDAg-S比HDAg-S或未进行法尼基化修饰的HDAg-L更有效地掺入VLP,但它的掺入效率远低于野生型HDAg-L;因此,有效的组装需要法尼基化修饰。